Publications by authors named "Minal A Barve"

Claim this Profile
P
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Nirav N Shah, Pier Luigi Zinzani, Michael Wang, Sunita D Nasta, Ewa Lech-Maranda, Minal A Barve

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach, Minal A Barve

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Anthony P Conley, Christina L Roland, Alberto Bessudo, Brian R Gastman, Victoria M Villaflor, Minal A Barve

Cancer Gene Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model.
Sibel Blau, Julio Antonio Peguero, Halle C F Moore, Ian Churchill Anderson, Minal A Barve

JCO Clin Cancer Inform· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Santosh Kesari, Alberto Bessudo, Brian R Gastman, Anthony P Conley, Victoria M Villaflor, Minal A Barve

Future Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1).
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve

J Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results.
Jermaine I Coward, Minal A Barve, Ganessan Kichenadasse, Kathleen N Moore, Paul R Harnett

Cancers (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, Chan Y Cheah, John M Pagel, Minal A Barve

Lancet· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, John K Chan, Minal A Barve

Lancet Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Frankie Ann Holmes, Beth A Hellerstedt, John E Pippen, Svetislava J Vukelja, Rufus P Collea, Minal A Barve

Cancer Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis